|
|
Vol. 17.00 – 9 January, 2026
|
|
|
|
|
|
|
In this cohort study with a target trial emulation design, sodium-glucose cotransporter 2 inhibitor use was associated with delayed hormone therapy failure in patients with prostate cancer, suggesting a potential oncologic benefit beyond glucose lowering. [JAMA Oncology]
|
|
|
|
|
|
PUBLICATIONSListed by the impact factor of the journal
|
|
|
|
|
|
Researchers developed a 2D mouse stem cell-derived prostate epithelial organoid model. In the organoid model, 5α-dihydrotestosterone promoted differentiation of basal into luminal cells, while transcriptomic analyses validated the model in comparison to 3D models and mouse prostate tissue.
[Nature Microbiology]
|
|
|
|
|
|
The authors demonstrated that inhibiting histone H4-lysine 20 methyltransferases SUV4-20H1 and SUV4-20H2 induces synthetic lethality in combination with the TOP2 poison etoposide in prostate cancer. [Cancer Research]
|
|
|
|
|
|
Scientists identified circUTRN, an androgen receptor-inhibited circRNA that was upregulated following neoadjuvant hormonal therapy and downregulated in prostate cancer tissues.
[Proceedings of the National Academy of Sciences of the United States of America]
|
|
|
|
|
|
Investigators revealed that SOX4 expression was increased in patients with prostate cancer with low PTEN levels, and the expression of SOX4 and PTEN was inversely correlated in patients with prostate cancer. [Molecular Cancer Research]
|
|
|
|
|
|
Researchers investigated the role and mechanisms of pseudopodium-enriched atypical kinase (PEAK) 1 in prostate cancer progression and docetaxel resistance.
[European Journal of Medical Research]
|
|
|
|
|
|
Investigators identified tyrosyl-DNA phosphodiesterase 2 (TDP2) as a key regulator within the tumor microenvironment and suggested its potential utility as both a prognostic biomarker and therapeutic target in prostate cancer. [PloS One]
|
|
|
|
|
|
|
|
The authors explore mRNA-based vaccines as a promising immunotherapy in prostate cancer. They discuss their mechanism of action, advantages in production and safety, and results from early clinical trials [NPJ Vaccines]
|
|
|
|
|
|
Scientists examine microbes from the skin, oral cavity, gut, urinary tract, and the prostate cancer microenvironment, summarizing how these communities affect prostate cancer initiation, progression, and therapeutic response. [NPJ Biofilms and Microbiomes]
|
|
|
|
|
|
|
|
Alessa Therapeutics announced that the US FDA has granted Fast Track designation for Enolen®, the Company’s lead product candidate for the treatment of low to intermediate risk, localized prostate cancer.
[Alessa Therapeutics]
|
|
|
|
|
|
Butterfly Medical announced the successful completion of the final 12-month follow-up for all patients in its international pivotal clinical study. The landmark study was designed to evaluate the safety and efficacy of the Butterfly Prostatic Retraction Device, a first-line interventional therapy for BPH. [Butterfly Medical (BioSpace)]
|
|
|
|
|
|
|
|
March 15-20, 2026 Ventura, California, United States
|
|
|
|
|
|
|
|
|
|
|
Ohio State University – Columbus, Ohio, United States
|
|
|
|
|
|
|
|
|
Washington University Medical Campus – St. Louis, Missouri, United States
|
|
|
|
|
|
|
St. Jude Children’s Research Hospital – Memphis, Tennessee, United States
|
|
|
|
|
|
|
St Jude Children’s Research Hospital – Memphis, Tennessee, United States
|
|
|
|
|
|